SABS - Latest News

SAB Biotherapeutics, Inc. (SABS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $37.9M. Beta to the broader market is 0.56.

The article list below shows the most recent SABS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent SABS Headlines

SAB Biotherapeutics Q1 Earnings Call Highlights

marketbeat.com - May 12, 2026

SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinica

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

globenewswire.com - May 12, 2026

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline da

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

globenewswire.com - May 5, 2026

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

globenewswire.com - Apr 22, 2026

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with

SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes

seekingalpha.com - Apr 15, 2026

SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candidate targeting both stage 2 and stage 3 patients. S

How News Affects SABS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SABS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked SABS news questions

What is the latest SABS news headline?

The most recent SABS headline (May 12, 2026) is "SAB Biotherapeutics Q1 Earnings Call Highlights". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the SABS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What SABS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual SABS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.